Merck drops TIGIT asset and LAG-3 program, discontinuing several phase 3 trials
Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is proving that it’s no different. | In a day that already included discontinuations from Roche and Foghorn Therapeutics,
Merck discontinues development of 2 experimental cancer drugs after trial failures
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials. The pharmaceutical giant's decision comes after several setbacks for the drugs,
Merck discontinues clinical development programs for vibostolimab, favezelimab
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody,
Merck to discontinue Phase 3 KeyVibe-003, KeyVibe-007 trials
Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an
Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis
Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program.
Merck Ends Development of Two Experimental Cancer Drugs
Merck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its investigational cancer drugs vibostolimab and favezelimab, respectively. Merck’s decision followed a series of setbacks for both drugs,
The Pharma Letter1h
Merck & Co cuts TIGIT and LAG-3 programs
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...
pharmaphorum1d
End of the line for MSD's TIGIT, LAG-3 cancer drugs
One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...
BioPharma Dive2d
Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...
precisionmedicineonline19h
Merck to Discontinue Anti-TIGIT, Anti-LAG-3 Programs Based on Lackluster Results
The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.
Hosted on MSN4d
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy
Teos' Phase II trial for inupadenant met its primary and secondary endpoints but offered little more than existing treatments ...
ENDPOINTS NEWS1d
Mer­ck winds down TIG­IT, LAG-3 pro­grams meant to tem­per Keytru­da ero­sion
Merck discontinues TIGIT drug vibostolimab and LAG-3 drug favezelimab after Phase 3 failures with Keytruda in lung cancer and ...